Providing a real-time, high-resolution view into the artery during intervention may help to identify high-risk plaques associated with cardiovascular events. Additional uses could include views of hard to see stent deployments, and assessment of apposition, stent strut symmetry, side branch interaction, dissection, thrombus formation. Diagnostic applications could include plaque luminal characterization for better device selection, endothelization of prior placed stents.

To create an imaging device with micro-small components that can enter vessels and provide high-definition, real-time views of obscured lesions and at-risk plaques, requires closing manufacturing gaps by scaling up semi-conductor level manufacturing with highly precise robotics.

VerAvanti is an R&D intensive company developing unique components, software, electronics and robotic manufacturing processes. Engineering endoscopes with micro small probes ranging in size from 1.6mm: 4.8 Fr. To 0.95 mm.: 2.85 Fr., demands unique, highly-precise, manufacturing techniques.

Because the clinical dimensions of the device are too small for conventional manufacturing and larger than most semiconductor techniques, there is a “manufacturing gap” in the current market. To address this VerAvanti has establishedin-house MEMS (Micro-ElectroMechanical Systems) manufacturing and ISO-Class 8 Cleanroom using robotic work-cells. This enables precision-level quality and de-risks the product by minimizing direct human labor and standardizing assembly.

• 2016: SFE console design complete. Quality system certified to ISO 13485 by DEKRA (August 2016)

• 2015: Scale-ready infrastructure, implemented including quality systems, NetSuite ERP, CRM, and accounting system and other automated business processes
• 2014: Established Class-8 manufacturing and assembly clean room operation
• 2013: VerAvanti Inc. founded.  Acquired exclusive worldwide rights to license SFE technology patents
  • Series A and Series B round funded